• news.cision.com/
  • Medivir/
  • Marketing Authorization Application for Lipsovir® now validated by American and European regulatory authorities
English

Marketing Authorization Application for Lipsovir® now validated by American and European regulatory authorities

Report this content

Medivir announced today that the American (FDA) and European regulatory authorities have validated the NDA and Marketing Authorization Application for Lipsovir®.

The authorities will start the review process to evaluate the data submitted by Medivir. The outcome of this review is expected to be received in the late part of third quarter 2009.

Lipsovir® is a topical product for prevention and treatment of cold sores. Lipsovir® is a patented combination of hydrocortisone (an anti-inflammatory agent) and acyclovir (an antiviral agent) in a proprietary cream base developed by Medivir.



For additional information please contact
Rein Piir, CFO & VP, Investor Relations at Medivir, +46 8 5468 3123 or +46 708 537292

For more information on Medivir, please see the company website www.medivir.se

Subscribe

Documents & Links